Aims: We investigated the influence of body mass index (BMI) on the prevalence of responder status in chronic heart failure patients after cardiac resynchronization therapy (CRT).
Methods: Data on 169 patients with resynchronization therapy were analyzed. Patients were categorized on the basis of the BMI measured at device implantation according to the WHO classification, as normal (BMI: 18.5–24.9 kg/m2), overweight (BMI: 25–29.9 kg/m2) or obese (BMI:≥30 kg/m2). Patients were considered responders if left ventricular ejection fraction was increased by at least 5% at 6-month follow-up.
Results: The mean age in the study population was 60.9±10.86 years (females 29%). The BMI subgroups did not exhibit any significant differences in baseline characteristics (age, gender, left ventricular ejection fraction or NYHA class). Elevated BMIs were associated with higher prevalence of responder status (overweight: 71.4%, obese: 63.0%) relative to subjects with a normal BMI (44.7%) (p=0.015).
Conclusions: In this CRT population, overweight status was associated with a more favorable response to CRT, indicating that the response may possibly be influenced by factors other than those directly related to the heart status or the technical details of the CRT.
1. D.H. Birnie A.S.L. Tang 2006 The problem of non-response to cardiac resynchronization therapy Curr Opin Cardiol 21 20 26.
2. N. Freemantle P. Tharmanathan M.J. Calvert W.T. Abraham J. Ghosh J.G.F. Cleland 2006 Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction — A systematic review and meta-analysis Eur J Heart Fail 8 433 440.
3. E.S. Chung A.R. Leon L. Tavazzi et al.2008 Results of the predictors of response to CRT (PROSPECT) trial Circulation 117 2608 2616.
4. S.A. Mollema G. Bleeker E. van der Wall M. Schalij J. Bax 2007 Usefulness of QRS duration to predict response to predict response to cardiac resynchronization therapy in patients with end-stage heart failure Am J Cardiol 100 1665 1670.
5. M. Gasparini M. Mantica P. Galimberti et al.2003 Is the left ventricular lateral wall the best lead implantation site for cardiac resynchronization therapy Pacing Clin Electrophysiol 26 1Pt2 162 168.
6. M. Haghjoo H.R. Bonakdar M.V. Jorat et al.2009 Effect of right ventricular lead location on response to cardiac resynchronization therapy in patients with end-stage heart failure Europace 11 356 363.
7. C. D'Ivernois J. Lesage P. Blanc 2008 Resynchronization: What if the left ventricular lead cannot reach the lateral or posterolateral wall? Pacing Clin Electrophysiol 31 1041 1045.
8. A. Achilli C. Peraldo M. Sassara et al.2006 Prediction of response to cardiac resynchronization therapy: The selection of candidates for CRT (SCART) study Pacing Clin Electrophysiol 29 Suppl2 S11 S19.
9. S.G. Molhoek J. Bax L. van Erven et al.2004 Comparison of benefits from cardiac resynchronization therapy in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy Am J Cardiol 93 860 863.
10. World Health Organization: Global database of body mass index. Available at: http://www.who.int/bmi/index.jsp. Accessed January 20, 2009.
11. R.M. Krauss M. Winston 1998 Obesity: Impact on cardiovascular disease Circulation 98 1472 1476.
12. S. Kenchaiah J.C. Evans D. Levy et al.2002 Obesity and the risk of heart failure N Engl J Med 347 305 313.
13. P. Poirier T.D. Giles G.A. Bray et al.2006 Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the obesity committee of the Council of Nutrition, Physical Activity, and Metabolism Circulation 113 898 918.
14. O. Divitiis S. Fazio M. Petitto et al.1981 Obesity and cardiac function Circulation 64 477 482.
15. M.A. Alpert B.E. Terry M. Mulekar et al.1997 Cardiac morphology and left ventricular function in normotensive morbidly obesee patients with and without congestive heart failure, and effect of weight loss Am J Cardiol 80 736 740.
16. J.P. Curtis J.G. Selter Y. Wang et al.2005 The obesity paradox body mass index and outcomes in patients with heart failure Arch InternMed 165 55 61.
17. B. Bozkurt A. Deswal 2005 Obesity as a prognostic factor in chronic symptomatic heart failure Am Heart J 150 1233 1239.
18. C.H. Davos W. Doehner M. Rauchhaus et al.2003 Body mass and survival in patients with chronic heart failure without cachexia: The importance of obesity J Card Fail 91 891 894.
19. G.C. Fonarow P. Srikanthan M.R. Costanzo et al.2007 An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry Am Heart J 153 74 81.
20. C. Schernthaner M. Pichler B. Strohmer 2007 Lower body mass index and atrial fibrillation as independent predictors for mortality in patients with implantable cardioverter defibrillator Croat Med J 48 59 67.
21. J. Cleland N. Freemantle S. Ghio et al.2008 Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response. A report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial J Am Coll Cardiol 52 438 445.
22. C.M. Yu B.G. Bleeker J.-H. Fung et al.2005 Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy Circulation 112 1580 1586.
23. M. Kubanek I. Málek J. Bytesnik et al.2006 Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months Eur J Heart Fail 8 832 840.
24. T.B. Horwich G.C. Fonarow M.A. Hamilton et al.2001 The relationship between obesity and mortality in patients with heart failure J Am Coll Cardiol 38 789 795.
25. K. Kalantar-Zadeh T.B. Horwich A. Oreopoulos et al.2007 Risk factor paradox in wasting diseases Curr Opin Clin Nutr Metab Care 10 433 442.
26. A.J. Moss W.J. Hall D.S. Cannom et al.2009 Cardiac-resynchronization therapy for the prevention of heart-failure events N Engl J Med 361 1329 1338.
27. C. Daubert M.R. Gold W.T. Abraham et al.2009 Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. Insights from the European cohort of the REVERSE (Resynchronization reverses remodeling in systolic left ventricular dysfunction) trial J Am Coll Cardiol 54 1837 1846.